GRI News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

GR

Mkt Cap

$3.1M

Volume

43.84K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” SegmentGRI Bio participated in a virtual investor segment discussing its Phase 2a study interim biomarker data for Idiopathic Pulmonary Fibrosis, highlighting potential therapeutic advances in treating inflammatory and fibrotic diseases using NKT cell modulators.GlobeNewswire Inc. · Jul 31, 2025

Windtree Announces the Addition of Leanne Kelly to Its Board of DirectorsWindtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.GlobeNewswire Inc. · Jan 13, 2025

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary CompoundsGRI Bio, a biotechnology company, announced that the European Patent Office has issued a decision to grant a patent for its NKT cell modulator GRI-0803 and its library of over 500 proprietary compounds. The company is focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases.GlobeNewswire Inc. · Dec 23, 2024

GRI Bio Announces Exercise of WarrantsGRI Bio, a biotechnology company, announced the exercise of existing warrants and the issuance of new warrants. The company intends to use the proceeds for working capital and general corporate purposes.GlobeNewswire Inc. · Oct 21, 2024

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series - GlobeNewswireGRI Bio, a biotechnology company, announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024, where the CEO will provide a corporate overview and business outlook.GlobeNewswire Inc. · Jul 15, 2024

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment - GlobeNewswireGRI Bio, a biotechnology company, announced the release of interim data from its ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF). The CEO discussed the significance of the data and its implications for the company's IPF program.GlobeNewswire Inc. · Jul 11, 2024

Cystic Fibrosis Therapeutics Research Report 2024: A Global $15.42 Billion Market by 2032 from $7.07 Billion in 2023 ... - GlobeNewswireThe global cystic fibrosis therapeutics market is expected to grow from $7.07 billion in 2023 to $15.42 billion by 2032, driven by the increasing prevalence of the disease, advancements in treatment, and supportive legislation.GlobeNewswire Inc. · Jul 4, 2024

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care MedicineData demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in miceGlobeNewswire Inc. · Jul 2, 2024

GRI Bio to Present at the 8th Annual IPF SummitLA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.GlobeNewswire Inc. · Jul 1, 2024

GRI Bio Announces Closing of $4.0 Million Public OfferingLA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 2,185,793 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,185,793 shares of common stock and Series C-2 warrants to purchase up to 2,185,793 shares of common stock (all the warrants, collectively, the "Series Warrants"), at a combined purchase price of $1.83 per share (or per common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an exercise price of $1.83 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series Warrants. The Series C-1 warrants expire on the five-year anniversary of the initial exercise date. The Series C-2 warrants expire on the eighteen-month anniversary of the initial exercise date.GlobeNewswire Inc. · Jun 28, 2024

GR

GRIGRI Bio, Inc. Common Stock

GRI

Pay with—

Available Balance0.00

Your PositionYou don't own any GRI yet.

Related Tickers

Earnings